- CAS No: 129938-20-1
- Molecular Formula:C21H24ClNO
- Molecular weight:341.88
- Purity: 98%
- Appearance: White crystalline powder
- Grade:Pharmaceutical Grade
Dapoxetine hydrochloride is a drug that is used to treat premature ejaculation in men. It is available by prescription and is taken orally, prior to sexual intercourse. The drug belongs to the class called serotonin reuptake inhibitors (SSRIs), which have mainly been used to treat depression.
Sexual dysfunction, including premature ejaculation, is an extremely common condition worldwide. The cause of premature ejaculation has not been fully elucidated, but may include both psychological and physiological factors. Premature ejaculation refers to a short ejaculation time, which can affect the satisfaction of both partners during sexual intercourse.
To treat premature ejaculation, both psychological and physiological factors need to be managed. From a pharmacological point-of-view, to treat the physiological aspect of premature ejaculation, dapoxetine hydrochloride is one of the first oral drugs to be made available. Psychological treatment may be given concomitantly, as the condition is multifactorial.
One of the possible adverse effects reported with SSRIs when used to treat depression is delayed ejaculation. This reported adverse effect led to the studies of dapoxetine hydrochloride, using the effect therapeutically. It is thought that serotonin may be involved in the inhibition of ejaculation. By blocking the serotonin reuptake in men suffering from premature ejaculation, the time to ejaculation may be prolonged.
Safety and tolerability
The cardiovascular safety profile of dapoxetine has been studied extensively during the drug development. Studies in men with PE showed a safety and well tolerate profile of dapoxetine with dosing of 30 and 60 mg. There is no cardiovascular adverse had been found.
Studies of SSRIs in patients with major psychiatric disorders prove that SSRIs are potentially associated with certain neurocognitive adverse effects such as anxiety, akathisia, hypomania, changes in mood, or suicidal thought. McMahon’s study in 2012 showed that dapoxetine has no effect on mood and is not associated with anxiety or suicidality.
The incidence of antidepressant discontinuation syndrome symptoms in men using dapoxetine to treat premature ejaculation has been described by reviewers as low and/or no different from the incidence of such symptoms in men withdrawn from placebo treatment. The lack of chronic serotonergic stimulation with on-demand dapoxetine minimizes the potentiation action of serotonin at synaptic cleft, thus decreasing the risk of DESS.